The Philadelphia chromosome: How a genetic swap changed the history of cancer treatment

Health · Published 3 October 2026 Swipe more like this →

In short: Chronic myelogenous leukemia was once a daunting diagnosis. Today, it is a landmark in medicine. By identifying a specific genetic error—a translocation between chromosomes 9 and 22—scientists transformed a lethal condition into a manageable one, proving that targeted therapy can effectively turn off the engine of cancer.

Chronic myelogenous leukemia (CML) is a cancer of the bone marrow that causes the uncontrolled production of myeloid white blood cells. Unlike many cancers, CML is defined by a clear genetic signature: the Philadelphia chromosome. Discovered in 1960 by Peter Nowell and David Hungerford, this abnormality occurs when sections of chromosomes 9 and 22 swap places. This translocation creates a fusion gene known as BCR-ABL, which produces an overactive protein called tyrosine kinase. This protein acts like a permanent 'on' switch for cell division, forcing blood cells to multiply rapidly and crowd out healthy marrow.

The disease typically progresses through three stages: the chronic phase, the accelerated phase, and the blast crisis. Most patients are diagnosed during the chronic phase, often incidentally through routine blood tests, as it is frequently asymptomatic. If left untreated, the disease advances to the blast crisis, a dangerous stage characterized by bone marrow failure, severe infection, and bleeding. While radiation exposure is a known risk factor—historically linked to survivors of the Hiroshima and Nagasaki bombings—most cases of CML have no identifiable cause and are not inherited from parents.

The treatment of CML was revolutionized by the development of tyrosine kinase inhibitors (TKIs). These targeted medicines block the activity of the BCR-ABL protein, effectively halting the cancer's growth. Since their introduction, these drugs have dramatically improved survival rates, allowing many patients to achieve long-term remission and maintain a good quality of life. In some cases, patients who achieve deep, sustained remission may even be able to stop medication under medical supervision. For those whose disease progresses or becomes resistant to TKIs, stem cell or bone marrow transplants remain a critical therapeutic option.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• When chromosomes swap pieces, the results can be life-saving or life-threatening
• When blood cell production turns into an uncontrollable cycle of replication
• How blood cancer research is decoding the hidden mechanics of aging and disease
• Leukemia is the most common cancer in children
• Acute myeloid leukemia is a fast-moving blood cancer that demands immediate medical attention.
• When leg veins fail, blood pools and pressure builds, but relief is often simple.
• When your immune system turns against your nerves, what happens to the body?
• A misfolded protein is spreading through deer herds across North America
• Chronic conditions are no longer just terminal illnesses, but a persistent, lifelong global challenge.
• Columbus's scouts found Cubans smoking rolled leaves, and Europe soon followed
• The hidden health cost of undiagnosed mood disorders
• Machine-made cigarettes turned a niche into a pandemic

More in Health, medicine and disease · More in Health · Latest · A–Z · All topics